The effects of buspirone on the behaviour of control and stressed mice

Journal of Physiology and Pharmacology

Volumn 49, Issue 1, 1998, Pages 175-186

  Pokk, P ^a   Zharkovsky, A ^a  

^a UNIVERSITY OF TARTU   (Estonia)

Author keywords

Buspirone; Hole board; locomotor activity; Plus maze; Sleep deprivation; Stress

Indexed keywords

BUSPIRONE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; MAZE TEST; MOUSE; NONHUMAN; SEDATION; STRESS; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; BEHAVIOR, ANIMAL; BUSPIRONE; EXPLORATORY BEHAVIOR; MALE; MAZE LEARNING; MICE; MICE, INBRED STRAINS; MOTOR ACTIVITY; STRESS;

EID: 0031982382     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Mark J, Heiner L, Mandel P, Godin Y. Norepinephrine turnover in brain and stress reactions in rats during paradoxical sleep deprivation. Life Sciences 1969; 8: 1085-1093.
2. Morden B, Mitchell G, Dement W. Selective REM sleep deprivation and compensation phenomena in the rat. Brain Research 1967; 5: 339-349.
3. Fratta W, Collu M, Martelotta MC, Pichiri M, Muntoni F, Gessa GL. Stress induced insomnia: opioid-dopamine interactions. Eur J Pharmacol 1987; 142: 437-440.
4. Fratta W, Fadda P, Martelotta MC, Gessa GL. Dopamine and neuropeptides interactions in sleep deprivation. Clinical Neuropharmacology 1990; 13: 386-388.
5. Pokk P, Zharkovsky A. The effects of drugs acting at GABA-Benzodiazepine-Barbiturate receptor complex on the behaviour of sleep deprived mice. Pharmacol Toxicol 1995; 76: 23-28.
6. Pokk P, Liljequist S, Zharkovsky A. Ro 15-4513 potentiates, instead of antagonizes, ethanol-induced sleep in mice exposed to small platform stress. Eur J Pharmacol 1996; 317: 15-20.
7. Pokk P, Zharkovsky A. The effects of flumazenil, Ro 15-4513 and β-CCM on the behaviour of control and stressed mice in the plus-maze test. J Physiol Pharmacol 1997; 48: 253-261.
8. Pokk P, Kivastik T, Sobol D, Liljequist S, Zharkovsky A. Is upregulation of benzodiazepine receptors a compensatory reaction to reduced GABAergic tone in the brain of stressed mice? Naunyn Schmiedebergs' Arch Pharmacol 1996; 354: 703-708.
9. Squires RF. Benzodiazepine receptors. In: Handbook of Neurochemistry. Receptors in the Nervous System. A Lajtha (ed). Plenum Press, 1984, pp. 261-306.
10. Squires RF. Ligand and ion site interactions in GABA and benzodiazepie receptor complexes. In Benzodiazepine/GABA Receptors and Chloride Channels: Structural and Functional Properties, New York, Alan R Liss, Inc., 1986, pp. 209-224.
11. Glaser T, Traber J. Buspirone: action on serotonin receptors in calf hippocampus. Eur J Pharmacol 1985; 88: 137-138.
12. A receptors. Biological Psychiatry 1985; 20: 971-979.
13. Bourin M, Malinge M. Controlled comparison of the effects and abrupt discontinuation of buspirone and lorazepam. Prog Neuro-Psychopharmacol Biol Psychiatry 1995; 19: 567-575.
14. Taylor DP, Moon SL. Buspirone and related compounds as alternative anxiolytics. Neuropeptides 1991; 19: 15-19.
15. Gedye A. Buspirone alone or with serotonergic diet reduced aggression in a developmentally disabled adult. Biol Psychiat 1991; 30: 88-91.
16. Rickets K, Amsterdam J, Clary C et al. Buspirone in depressed out-patients: a controlled study. Psychopharmacol Bulletin 1990; 26: 163-167.
17. Cole JC, Rodgers RJ. Ethological evaluation of the effects of acute and chronic buspirone treatment in the murine elevated plus-maze test: comparison with haleperidol. Psychopharmacology 1994; 114: 288-296.
18. 1A receptor agonists and NMDA receptor antagonists in the social interaction test and the elevated plus maze. Eur J Pharmacol 1989; 169: 1-10.
19. Lee C, Rodgers RJ. Effects of buspirone on antinociceptive and behavioural responses to the elevated plus-maze in mice. Behav Pharmacol 1991; 2: 491-496.
20. 1A receptor agonist, buspirone, after prolonged chronic administration. Eur J Pharmacol 1993; 239: 69-73.
21. Wada T, Fukuda N. Effects of DN-2327, a new anxiolytic, diazepam and buspirone on exploratory activity of the rat in an elevated plus-maze. Psychopharmacology 1991; 104: 444-450.
22. Andrews N, File SE. Handling history of rats modifies behavioural effects of drugs in the elevated plus-maze test of anxiety. Eur J Pharmacol 1993; 235: 109-112.
23. Moser PC. An evaluation of the elevated plus-maze test using the novel anxiolytic buspirone. Psychopharmacology 1989; 99: 48-53.
24. Pellow S, Johnson AL, File SE. Selective agonists and antagonists fo 5-hydroxytryptamine receptor subtypes and interactions with yohimbine and FG 7142 using the elevated plus-maze in the rat. J Pharm Pharmacol 1987; 39: 917-928.
25. McCloskey TC, Paul BK, Commissaris RL. Buspirone effects in an animal conflict procedure: comparison with diazepam and phenobarbital. Pharmacol Biochem Behav 1987; 27: 171-175.
26. Joly D, Sanger DJ. Social competition in rats: a test sensitive to acutely administered anxiolytics. Behav Pharmacol 1991; 2: 205-213.
27. Shimada T, Matsumoto K, Osanai M, Matsuda H, Terasawa K, Watanabe H. The modified light/dark transition test in mice: evaluation of classic and putative anxiolytic and anxiogenic drugs. Gen Pharmacol 1995; 26: 205-210.
28. Sanchez C. Serotonergic mechanisms involved in the exploratory behaviour of mice in a fully automated two-compartment black and white test box. Pharmacol Toxicol 1995; 77: 71-78.
29. Matto V, Harro J, Allikmets L. The effects of cholecystokinin A and B receptor antagonists on exploratory behaviour in the elevated zero-maze in rat. Neuropharmacology 1997; 36: 389-396.
30. Vale NB, Leite JR. Decreased susceptibility to local anesthetics-induced convulsions after paradoxical sleep deprivation. Psychopharmacology 1988; 94: 138-140.
31. File SE, Wilks LJ, Mabbutt PS. Withdrawal, tolerance and sensitization after a single dose of lorazepam. Pharmacol Biochem Behav 1989; 31: 937-940.
32. Durcan MJ, Lister RG. Does directed exploration influence locomotor activity in a holeboard test? Behav Neural Biol 1989; 51: 121-125.
33. Pellow S, Chopin P, File SE, Briley M. Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 1985; 14: 149-167.
34. Lister RG. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 1987; 92: 180-185.
35. Dawson GR, Crawford SP, Collinson N, Iversen SD, Tricklebank MD. Evidence that the anxiolytic-like effects of chlordiazepoxide on the elevated plus maze are confounded by increases in locomotor activity. Psychopharmacology 1995; 118: 316-322.
36. Rodgers RJ, Lee C, Shepherd JK. Effects of diazepam on behavioural and antinociceptive responses to the elevated plus-maze in male mice depend upon treatment regimen and prior maze experience. Psychopharmacology 1992; 106: 102-106.
37. McBlane JW, Handley SL. Effects of two Stressors on behaviour in the elevated X-maze: preliminary investigation of their interaction with 8-OH-DPAT. Psychopharmacology 1994; 116: 173-182.
38. File SE, Wardill AG. The reliability of the holeboard apparatus. Psychopharmacology 1975; 44: 53-59.
39. Lister RG. Interactions of Ro 15-4513 with diazepam, sodium pentobarbital and ethanol in a holeboard test. Pharmacol Biochem Behav 1987; 28: 75-79.
40. Steenbergen HL, Farabollini F, Heinsbroek RP, van de Poll NE. Sex-dependent effects of aversive stimulation on holeboard and elevated plus-maze behaviour. Behav Brain Res 1991; 43: 159-165.
41. Lister RG. Ethologically-based animal models of anxiety disorders. Pharmacol Ther 1990; 46: 321-340.
42. June HL, Lewis MJ. Interactions of Ro 15-4513, Ro 15-1788 (flumazenil) and ethanol on measures of exploration and locomotion in rats. Psychopharmacology 1994; 116: 309-316.
43. Santos R, Carlini EA. Serotonin receptor activation in rats previously deprived of REM sleep. Pharmacol Biochem Behav 1983; 18: 501-507.
44. Santos R, Carlini EA. Central responses to cholinergic drugs of REM sleep deprived rats. Pharmacol Biochem Behav 1988; 29: 217-221.
45. Matheson GK, Knowles A, Gage D et al. Modification of hypothalamic-pituitary-adrenocortical activity by serotonergic agents in the rat. Pharmacology 1997; 55: 59-65.
46. de Boer SF, Slangen JL, van der Guten J. Effects of chlordiazepoxide and buspirone on plasma catecholamine and corticosterone levels in rats under basal and stress conditions. Endocrinologia Experimentalis 1990; 24: 229-239.
47. de Boer SF, Slangen JL, van der Guten J. Effects of buspirone and chlordiazepoxide on plasma catecholamine and corticosterone levels in stressed and nonstressed rats. Pharmacol Biochem Behav 1991; 38: 299-308.
48. McNaughton N, Panickar KS, Logan B. The pituitary-adrenal axis and the different behavioral effects of buspirone and chlordiazepoxide. Pharmacol Biochem Behav 1996; 54: 51-56.
49. Goa KL, Ward A. Buspirone. A preliminary review of its pharmacologie properties and therapeutic efficacy as an anxiolytic. Drugs 1986; 32: 114-129.
50. Fulton B, Brogden RN. Buspirone - and updated review of its clinical pharmacology and therapeutic applications. CNS Drugs 1997; 7: 68-88.